Form 4: Seer Inc. CEO Omid Farokhzad Reprices Stock Options to $2.00

Seer, Inc. CEO Omid Farokhzad reports repricing of employee stock options to $2.00 per share, affecting options with original exercise prices above this level.

Summary

• Omid Farokhzad, CEO and Chair of Seer, Inc., filed a Form 4 detailing changes in beneficial ownership due to a stock option repricing.
• The repricing, effective October 4, 2024, lowered the exercise price of certain employee stock options to $2.00 per share.
• This change applies to nonstatutory options with exercise prices greater than $2.00 held by continuing employees as of the effective date.
• Farokhzad's transactions involve multiple employee stock options with varying original exercise prices and vesting schedules.
• The repricing does not alter the vesting schedules, expiration dates, or the number of shares underlying the options.
• A premium exercise price applies if an employee exercises a repriced option before the end of a retention period ending on April 4, 2026, upon a change in control, or death/disability.
• Some options are subject to performance-based vesting criteria tied to Seer's stock price reaching 150% of the original or repriced exercise price by specific dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The repricing is a common practice to retain and incentivize employees, but it also carries potential dilution risks for shareholders. The impact depends on the company's future performance.

Positives

• The stock option repricing may incentivize employees by making options more accessible.
• The repricing could improve employee morale and retention.
• The repricing aligns employee incentives with shareholder value by encouraging stock price appreciation.

Negatives

• The repricing could dilute existing shareholders if a significant number of options are exercised.
• The premium exercise price condition may create uncertainty for employees considering exercising options before the end of the retention period.

Risks

• Failure to achieve the stock price hurdle for performance-based options could result in unvested options.
• The retention period condition may discourage early exercise of options.
• The repricing may not have the intended effect of incentivizing employees if the stock price does not appreciate significantly.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and performance-based criteria of the options.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has declined significantly. It's common in the biotech industry, where stock prices can be volatile.

Comparison to Industry Standards

• Comparing Seer's option repricing to companies like Adaptive Biotechnologies or NanoString Technologies, which have also faced stock volatility, would provide context.
• The $2.00 exercise price is a key benchmark; comparing it to the median exercise price of options granted by similar-stage companies in the life sciences sector would be informative.
• The vesting schedules and performance-based criteria should be assessed against industry norms to determine if they are competitive.

Stakeholder Impact

• Shareholders may experience dilution if options are exercised.
• Employees with options benefit from the lower exercise price.
• The repricing aims to improve employee morale and retention, potentially benefiting the company's long-term performance.

Next Steps

• Employees will decide whether to exercise their repriced options.
• Seer's stock price performance will determine whether performance-based options vest.
• The company will continue to monitor the effectiveness of the repricing in incentivizing employees.

Key Dates